Asahi Kasei regains global rights to thrombomodulin through Artisan buyout
This article was originally published in Scrip
The pharma division of Japan's Asahi Kasei has bought out the private US venture Artisan Pharma, in which it was already an investor and to which it had licensed the recombinant human thrombomodulin-alfa product ART-123 for development outside Asia.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.